

Reference number(s)
2298-H

SPECIALTY QUANTITY LIMIT PROGRAM

OCALIVA (obeticholic acid)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of primary biliary cholangitis fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Initial Limit	FDA-recommended dosing
Ocaliva 5 mg tablets	30 per 30 days	Non-cirrhotic or compensated Child-Pugh Class A: 5 mg or 10 mg once daily
Ocaliva 10 mg tablets		Child-Pugh Class B/C or prior decompensation event: Start at 5 mg once weekly and titrate to 5 mg or 10 mg twice weekly

III. REFERENCE

- Ocaliva [package insert]. New York, NY: Intercept Pharmaceuticals, Inc.; February 2018.